HC Wainwright Has Bullish Forecast for KALV Q2 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Investment analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for KalVista Pharmaceuticals in a report released on Thursday, March 12th. HC Wainwright analyst A. Fein now anticipates that the specialty pharmaceutical company will post earnings per share of ($0.42) for the quarter, up from their prior forecast of ($0.46). HC Wainwright currently has a “Buy” rating and a $37.00 target price on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share. HC Wainwright also issued estimates for KalVista Pharmaceuticals’ Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($1.23) EPS, FY2028 earnings at $2.25 EPS, FY2029 earnings at $3.56 EPS and FY2030 earnings at $3.83 EPS.

Other research analysts have also issued reports about the stock. Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. TD Cowen reissued a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Needham & Company LLC boosted their target price on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.40.

KalVista Pharmaceuticals Price Performance

KALV stock opened at $16.56 on Monday. The firm has a 50 day moving average of $15.80 and a 200-day moving average of $14.33. The firm has a market capitalization of $837.11 million, a P/E ratio of -4.19 and a beta of -0.35. KalVista Pharmaceuticals has a 12 month low of $9.23 and a 12 month high of $19.00. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its stake in shares of KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 1,292 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in KalVista Pharmaceuticals in the third quarter worth approximately $55,000. Wolverine Asset Management LLC purchased a new position in KalVista Pharmaceuticals during the 3rd quarter worth $57,000. KLP Kapitalforvaltning AS bought a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at $63,000. Finally, Truvestments Capital LLC raised its position in KalVista Pharmaceuticals by 253.8% during the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,360 shares in the last quarter.

Insiders Place Their Bets

In related news, CEO Benjamin L. Palleiko sold 6,693 shares of the business’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $16.08, for a total transaction of $107,623.44. Following the completion of the transaction, the chief executive officer owned 451,815 shares in the company, valued at $7,265,185.20. The trade was a 1.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Brian Piekos sold 1,767 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $27,512.19. Following the completion of the sale, the chief financial officer owned 13,762 shares in the company, valued at approximately $214,274.34. The trade was a 11.38% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 33,378 shares of company stock valued at $522,290 over the last quarter. 4.30% of the stock is currently owned by insiders.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.